Nanordica Medical

08/04/2026

A randomized controlled trial published in the Journal of Wound Care concludes that Nanordica’s Premotiv® dressing is both safe and effective for treating diabetic foot ulcers.

A randomized controlled trial at the largest Estonian hospital, Põhja-Eesti Regionaalhaigla, included 30 patients with diabetic foot ulcers. Patients were randomly assigned into two groups: Group 1 was treated with silver ion (Ag+) wound dressings, while Group 2 was treated with Nanordica Advanced Antibacterial Wound Dressings with Premotiv® nanotechnology. Both groups were treated for 1 week with 3 dressing changes. Efficacy was measured by wound area size reduction, bacterial load control and quality of life scores. Safety outcomes were based on adverse events and blood levels.

Consistently better results were observed in nearly all efficacy and safety endpoints for patients treated with Nanordica Premotiv® dressings. By the end of the active treatment, which lasted for one week, the wound area decreased by 43% in the Nanordica dressing group, compared to a 13% reduction in the Ag+ dressing group. While the mean bacterial load remained stable in the Nanordica group, it increased in the Ag+ dressing group. Quality of life scores also improved in the Nanordica group.

The study indicated that the Premotiv® concept works, as Nanordica Advanced Antibacterial Wound Dressing is designed to both prevent infection and promote wound closure simultaneously.

Nanordica Advanced Antibacterial Wound Dressing is expected to receive regulatory approval and become available for distribution in Q4 2026.

We thank medical doctors and nurses contributing to the clinical trial: Dr. Helen Ilumets, Dr. Tiiu Kaha, Dr. Mart Roosimaa, Dr. Grigory Vasiliev, Tiina Mitt, Dr. Jelena Kostjuk, Dr. Helena Tern, Dr. Helvig Nõmm, Dr. Pille Rudenko, Dr. Halliki Kodar, Dr. Valdo Toome and Prof. David Russell, and the entire Nanordica Medical.

The link to the original publication in the Journal of Wound Care is in the comments.

12/03/2026

Nanordica Medical has been recognized by SmartTRAK, a leading wound care market intelligence platform, as one of four advanced wound dressing companies to watch in 2026. In its Outlook, SmartTRAK highlights the design of Nanordica’s Premotiv® dressing, developed to simultaneously prevent infection and promote natural wound healing while addressing the Silver Paradox in antimicrobial wound care.

As one of the largest clinical trials in the field nears completion, Nanordica is preparing to bring the Premotiv® dressing to patients in Europe in 2026, followed by US market entry in 2027.

Read the article via the link in the comments.

14/11/2025

Today is World Diabetes Day! Nanordica Medical draws attention to the increasing prevalence of diabetes and to the problem of diabetic foot ulcers and invites you to the clinical trial!

The study will be carried out in the largest hospitals in Estonia: East Tallinn Central Hospital (principal investigator: irina.djatsenko@itk.ee) and the North Estonia Medical Centre (principal investigator: anu.ambos@regionaalhaigla.ee).

Patients with diabetes and an ulcer of up to 4 cm on the foot that has not healed within 4 weeks are eligible for the study.

For more information, visit our web page and register your interest: https://www.nanordica.com/kliiniline-uuring

27/10/2025

Nanordica Medical innovation got introduced in an online magazine.

Latest in professional industrial tech

23/09/2025

Diabeetilise jalahaavandi uuring

19–34% diabeedihaigetel tekib diabeedi tüsistusena jalahaavand, mis ei parane. See teeb diabeetilisest jalahaavandist kõige levinuma kroonilise haavandi. Tõhusa ravi puudumisel 50-60% diabeetilistest jalahaavanditest infitseeruvad ja neist 20% juhtudel viib see varba või alajäseme amputatsioonini.

Järgides parima ravi põhimõtteid, mis on kajastatud IWGDF 2023 ravijuhendites ja uues Eesti ravijuhendis, on Nanordica Medical OÜ kavandanud kliinilise uuringu. See mitmekeskuseline rahvusvaheline uuring kaasab 11 keskust Eestis ja Hispaanias. Eesmärk on hinnata Nanordica Medical poolt välja arendatud Premotiv® haavasideme ohutust ja efektiivsust ning võrrelda seda standardravis kasutatava traditsioonilise antibakteriaalse haavasidemega diabeetiliste jalahaavanditega patsientidel.

Uuring viiakse läbi Eestis suurimates haiglates: Ida-Tallinna Keskhaiglas (irina.djatsenko@itk.ee), Põhja-Eesti Regionaalhaiglas (anu.ambos@regionaalhaigla.ee) ja Tartu Ülikooli Kliinikumis (maire.lubi@kliinikum.ee).

Saa rohkem teada uuringust ja registreeri huvi: https://www.nanordica.com/kliiniline-uuring

Eesti Õdede Liit Diabeedispetsialistid Jalahooldus kogu perele

https://www.diabetes.ee/avaleht/diabeetilise-jalahaavandi-uuring-2025

12/09/2025

ETV+ tegi hiljuti saate diabeedist, diabeetilistest jalahaavanditest ning meie lahendusest.

Saadet saab järele vaadata alloleva lingi kaudu (vene keeles, eestikeelsete subtiitritega):

https://jupiter.err.ee/1609782074/ochevidec?t=1979

Diabeetiliste halahaavanditega patsiendid on endiselt oodatud meie kliinilisse uuringusse. Eestikeelne lisainfo on esimeses kommentaaris.

2025.09.11 20:30. Токсичная рабочая среда в эстонских школах: большинство жалоб в Инспекцию труда поступает из образовательных учреждений страны. Кристьян Пихл разбирал ....

08/09/2025

📢 We are proud to announce that our Quality Management System has been certified according to the ISO 13485:2016 standard, the internationally recognized benchmark for quality in medical device manufacturing.

This certification is a key milestone toward the market authorization, ensuring that our processes meets the highest standards for safety, consistency, and performance.

Congratulations to the entire Nanordica Medical team and collaborators who helped us achieve this milestone!

26/08/2025

📢 If you know a patient with a chronic diabetic foot ulcer in Estonia or Spain, please refer them to our clinical study. All participants receive the best possible care and close medical follow-up as part of our clinical trial on our first product, an advanced antibacterial wound dressing.

We have just opened 6 new trial centers — 3 in Estonia and 3 in Spain:

Estonia:
Tartu University Hospital (Tartu Ülikooli Kliinikum)
Ida-Tallinna Keskhaigla
Põhja-Eesti Regionaalhaigla

Spain:
CS IDEhA Hospital de Alcorcón (Madrid) ( de al
Donostiako Ospitalea - Hospital Donostia
Hospital Universitario Ramón y Cajal (Madrid)

Already participating centers:
Universidad Complutense de Madrid (UCM) with PI of the study Dr. Prof. José Luis Lázaro-Martínez
Clínica Universitaria de Podología de la Universidad de León
Hospital Puerto del Mar, Cádiz
Centro de salud Arcos de la Frontera
Centro de salud San Benito

For more information, contact our medical doctors:
Dr. Mart Roosimaa
Dr. Grigory Vasiliev

👉 Please take a look at the additional information about the trial in the comments.

📢 Thank you for sharing and spreading the word!

24/05/2025

🩹 Absolutely new technology in the wound healing world! Scientists developed a bandage that can both stop infections and speed up healing.

That’s exactly what Tallinn-based Nanordica Medical is doing with its revolutionary low-silver wound dressing. This is also built to tackle one of the toughest challenges in diabetes care: chronic foot ulcers.

🔬 Backed by Estonian research and heading into major trials in Spain, it could change care for diabetic people and beyond.

Could this be the future of smarter healing? 💡

🔗 Read more: https://researchinestonia.eu/2025/05/21/next-gen-bandage-wound-recovery/
Or link in the comments! 👇

21/01/2025

Täna on meil kirjatükk eestikeelsele lugejale! 🇪🇪

Kas soovid teada, kuidas sai alguse Nanordica Medical ja kuidas me jõudsime viirusevastastest maskidest bakterivastaste haavasidemeteni ning teadlastest ettevõtjateks? Loe Ebveliis Vaaksi artiklit TalTech - Tallinn University of Technology Trialoogist!

Artikli leiad (eesti keeles) allolevast kommentaarist 👇.

Suur tänu KBFI Keskkonnatoksikoloogia laborile, Tehnopolile, Health Foundersile, Eesti Teadusagentuurile, EAS-ile ja Põhja-Eesti Regionaalhaiglale, kes olid meiega algusest peale kaasas!

15/01/2025

We are happy to announce that we started one of the world’s most ambitious clinical trials in wound care on the most challenging wounds: diabetic foot ulcers (DFU). The trial, involving 5 clinical centers and 170 patients, is coordinated by the leading international DFU expert, Prof. Dr. José Luis Lázaro-Martínez.

In this trial, the safety and performance after treatment with Nanordica Medical wound dressing is compared to those of one of the leading wound dressings. The primary endpoint of the study is a complete wound closure at 12 weeks, together with several secondary endpoints. Our ambition is to advance evidence-based wound care and contribute to the best practices in treating diabetic foot ulcers and beyond.

Nanordica advanced antibacterial wound dressing is made of natural silk nanofibers containing Premotiv nanotechnology. This design represents a novel concept in wound care aiming to PREvent infection and proMOTe wound closure simultaneously, leading to faster wound healing.

The study is expected to finish in March 2026 and is co-financed by the EIC Accelerator project. More information is in comments. If you wish collaborate within the study, please get in touch with our Chief Clinical Officer Dr. Grigory Vasiliev.

In the picture is the Principal Investigator of the clinical study Prof. Dr. José Luis Lázaro-Martínez (Complutense University of Madrid, Spain) and Nanordica Medical’s Chief Clinical Officer Dr. Grigory Vasiliev responsible for the study design.